首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1077262

溶瘤病毒療法的全球市場 - 2022年～2029年

Global Oncolytic Virotherapy Market - 2022-2029

出版日期: 2022年05月19日 | 出版商:

DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告提供全球溶瘤病毒療法市場相關調查，提供市場概要，以及各治療類型，各用途，各地區趨勢，競爭情形，及加入此市場的主要企業簡介等資訊。

簡介
- 市場規模分析，及與前一年同期比較成長分析(%)、各治療類型
- 市場魅力指數，各治療類型
腺病毒為基礎的溶瘤病毒
- 簡介
- 市場規模分析，100萬美元(2020年～2029年)，及與前一年同期比較成長分析(%)(2021年～2029年)
HSV為基礎的溶瘤病毒
其他

第8章全球溶瘤病毒療法市場-各用途

簡介
- 市場規模分析，及與前一年同期比較成長分析(%)、各用途
- 市場魅力指數，各用途
上顎骨的重度萎縮
- 簡介
- 市場規模分析，100萬美元(2020年～2029年)，及與前一年同期比較成長分析(%)(2021年～2029年)
黑色素瘤
前列腺癌
乳癌
卵巢癌
肺癌
其他

第9章全球溶瘤病毒療法市場-各地區

簡介
- 市場規模分析，100萬美元(2020年～2029年)，及與前一年同期比較成長分析(%)(2021年～2029年)，各地區
- 市場魅力指數，各地區
北美
歐洲
南美
亞太地區
中東·非洲

第10章全球溶瘤病毒療法市場-競爭情形

第11章全球溶瘤病毒療法市場-企業簡介

Amgen Inc
AstraZeneca
Shanghai Sunway Biotech Co., Ltd
TILT Biotherapeutics Ltd
Oncorus, Inc
Takara Bio Inc
Vyriad
Transgene SA
Lokon Pharma AB
Pfizer Inc
Roche

第12章全球溶瘤病毒療法市場-DataM

簡介目錄

Product Code: DMPH5020

Market Overview

The global oncolytic virotherapy market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Oncolytic viruses are the genetically engineered or naturally occurring viruses that selectively replicate in and kill cancer cells without harming the normal tissues. It mainly aims at modifying the genetic material for the treatment of the disease. Oncolytic virus therapy is a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person's genes.

Market Dynamics

The global oncolytic virotherapy market growth is driven by the rising research and development on cancer treatment using oncolytic virotherapy and the increasing prevalence of cancer are boosting the growth of oncolytic virotherapy market.

Rising research and development on cancer treatment using oncolytic virotherapy is expected to hold the largest share in this market segment

According to the data published by International Agency for Research on Cancer (IARC), in 2020, 19.3 million new cases and 10 million deaths from cancer were projected globally, respectively.

The market's expansion can be ascribed to the rising occurrence of rare cancers, the need to cure them, increased demand for better and more effective therapies, and an increase in the geriatric population. According to the World Health Organization (WHO) statistics, regions including Northern Africa and Western Asia, South America, the Caribbean, and Southeast Asia could face sharp increases of over 75% in the number of cancer deaths in 2020 compared to 2000.

The major factors expected to grow over the projected horizon are increasing awareness of oncolytic virus therapy and its benefits in treatments, advanced imaging technology, and rising adoption of cutting-edge cancer treatments. It has become a most promising therapy in cancer treatment in the new era. Many pharmaceutical companies are conducting various clinical trials of oncolytic viruses in combination with radiotherapy, immune checkpoint inhibitors, and chemotherapeutic agents, showing immense effects and progress in cancer treatments. In 2020, T-VEC, RIGVIR, and Oncorine oncolytic viral drugs were approved for cancer treatments having good therapeutic results.

Few side effects associated with the oncolytic virus are likely to hamper the market growth

Side effects may differ according to the type of oncolytic virus and its target site and may also be influenced by the location and type of cancer and a patient's overall health. Because of their potential to infect healthy cells and stimulate overall immune activity, sometimes oncolytic viruses may cause the immune system to attack healthy cells, and their use may carry some risk of infection. Some common side effects associated with the currently approved oncolytic virus may include chills, fatigue, flu-like symptoms, injection site pain, nausea, and fever.

COVID-19 Impact Analysis

The COVID-19 outbreak had a dramatic impact on the nation's health sector. The fastest rate of growth experienced in the healthcare expenditure in 2020. The unprecedented pandemic at the initial stage resulted in the shutting down of the healthcare industry globally which resulted in the large-scale disruptions in manufacturing, supply, and demand activities resulting in the cancellation of the orders and decline in exports. However, the precautionary measures taken by governments like social distancing and restrictions have severely disrupted the patient's treatments in hospitals. As per the statistics published by the Centers for Medicare and Medicaid Services (CMS), Federal government spending for health care grew 36.0% in 2020, significantly faster than the 5.9% growth in 2019. This faster growth was largely in response to the COVID-19 pandemic. The pandemic and emergence of variants continue to cause a concern and sudden and drastic downturn in the economic activity of the countries.

Segment Analysis

The adenoviruses-based oncolytic viruses' segment is expected to hold the largest share in this market segment

The Adenovirus-based Oncolytic Viruses segment held a huge market share and is expected to attain a significant market share in the forecast period. The growing usage demand due to their high accuracy in delivering the gene to the specific region has driven the market share in this segment.

Adenoviruses are double-stranded DNA viruses. They are considered excellent vectors due to their ability to induce innate and adaptive immune responses to deliver target antigens to the hosts.

The need for oncolytic virotherapy as a primary treatment is growing due to the increased prevalence of cancer. Many oncolytic viruses are being studied as a potential treatment for cancer in clinical trials. According to the American Cancer Society, 2021, breast and prostate cancer held the highest share, registering 281,550 and 248,530 cases.

Moreover, companies are also engaging in collaborations and agreements to increase their market share. For example, in August 2021, Calidi Biotherapeutics entered into an exclusive license agreement with the City of Hope and the University of Chicago for novel oncolytic virotherapy technology. The deal grants Calidi commercial exclusivity in using an oncolytic adenovirus (CRAd-pk-S-7) combined with a clinical-grade allogeneic neural stem cell line.

In January 2021, Theolytics, a European start-up, focuses on creating change in the oncolytic viral therapy field by using its phenotypic screening platform to discover and develop highly efficacious, targeted candidates suitable for intravenous delivery and optimized for a chosen cancer patient population.

Geographical Analysis

North America region holds the largest market share of global oncolytic virotherapy market

North America is expected to hold a high market share during the forecast period owing to the increasing patient population compared to other countries. The rising incidences of cancer in the United States boost the market growth. As per the 2021 report by the American Cancer Society, there were an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States in 2021. The other factors that are attributed to the market's growth are increasing awareness about different cancer treatments, the availability of advanced immune-oncology drugs in the region, and the growing healthcare spending in countries such as the United States. According to the statistics published by the Centers for Medicare and Medicaid Services (CMS), U.S. health care spending grew 9.7 percent in 2020, reaching USD 4.1 trillion or USD 12,530 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 19.7 percent.

Companies are also engaging in collaborations and agreements to increase their market share. In December 2021, Bionaut Labs announced a strategic partnership with Candel Therapeutics, Inc investigating Bionaut's remote-controlled microscale robots for precision delivery of Candel's oncolytic viral immunotherapy agents to specific brain tumors. In this collaboration, Bionaut Labs will apply its micro-robotic technology to deliver Candel's oncolytic viruses directly to brain tumors minimally invasive.

Competitive Landscape

The global oncolytic virotherapy market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc., Shanghai Sunway Biotech Co., Ltd., TILT Biotherapeutics Ltd., Oncorus, Inc., Takara Bio Inc., Vyriad, Transgene SA, Lokon Pharma AB, Pfizer Inc., Roche., AstraZeneca. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the oncolytic virotherapy globally. For instance, In January 2022, Siga technologies announced a preclinical collaboration with Bioarchitech for developing immunotherapy for cancer treatments. The research collaboration investigates the TPOXX (tecovirimat) in combination with Bioarchitech's proprietary 'vaccinia-based immunotherapy platform which utilizes engineered antibodies and other proteins within the genome of the oncolytic virus.

Key Companies to Watch

Amgen

Overview: Amgen was incorporated in 1980. The company is engaged in the research, development, and manufacturing of pharmaceutical products. Amgen is one of the world's leading biotechnology companies. The company offers a wide range of products for the treatment of central nervous system, neurosciences, ophthalmology, medical aesthetics, plastic surgery, dermatology, liver disease, inflammation, metabolic syndromes, and fibrosis.

Product Portfolio: It includes products like IMLYGIC (talimogene laherparepvec) is a prescription medication injected on the skin, beneath the skin, or in Their lymph glands to treat a type of skin cancer called melanoma when it can no longer be surgically removed.

Why Purchase the Report?

Visualize the composition of the oncolytic virotherapy market segmentation by therapy type, application, and region highlighting the key commercial assets and players.

Identify commercial opportunities in oncolytic virotherapy market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of oncolytic virotherapy market - level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players.

The global oncolytic virotherapy market report would provide an access to an approx. 50 market data table, 35 figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

1. Global Oncolytic Virotherapy Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Global Oncolytic Virotherapy Market - Market Definition and Overview

3. Global Oncolytic Virotherapy Market - Executive Summary

3.1. Market Snippet by Therapy Types
3.2. Market Snippet by Application
3.3. Market Snippet by Region

4. Global Oncolytic Virotherapy Market - Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers:
- 4.1.2. Rising research and development on cancer treatment
4.2. Restraints:
- 4.2.1. Few side effects associated with the oncolytic virus
4.3. Opportunity
4.4. Impact Analysis

5. Global Oncolytic Virotherapy Market - Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. PEST Analysis

6. Global Oncolytic Virotherapy Market - COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. Global Oncolytic Virotherapy Market - By Therapy Type

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
- 7.1.2. Market Attractiveness Index, By Therapy Type
7.2. Adenoviruses-based Oncolytic Viruses*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. HSV-based Oncolytic Viruses
7.4. Others

8. Global Oncolytic Virotherapy Market - By Application

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Severe Atrophy of Maxillary Bone*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Melanoma
8.4. Prostate Cancer
8.5. Breast Cancer
8.6. Ovarian Cancer
8.7. Lung Cancer
8.8. Others

9. Global Oncolytic Virotherapy Market - By Region

9.1. Introduction
- 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy type
- 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.2.5.1. U.S.
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy type
- 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.3.5.1. Germany
  - 9.3.5.2. U.K.
  - 9.3.5.3. France
  - 9.3.5.4. Italy
  - 9.3.5.5. Spain
  - 9.3.5.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy type
- 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. Brazil
  - 9.4.5.2. Argentina
  - 9.4.5.3. Rest of South America
9.5. Asia Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
- 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. China
  - 9.5.5.2. India
  - 9.5.5.3. Japan
  - 9.5.5.4. Australia
  - 9.5.5.5. Rest of Asia Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy type
- 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10. Global Oncolytic Virotherapy Market - Competitive Landscape

10.1. Competitive Scenario
10.2. Key Developments and Strategies
10.3. Company Share Analysis
10.4. Product Benchmarking
10.5. Key Companies to Watch
10.6. Company with disruptive technology

11. Global Oncolytic Virotherapy Market- Company Profiles

11.1. Amgen Inc*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Key Highlights
- 11.1.4. Financial Overview
11.2. AstraZeneca
11.3. Shanghai Sunway Biotech Co., Ltd
11.4. TILT Biotherapeutics Ltd
11.5. Oncorus, Inc
11.6. Takara Bio Inc
11.7. Vyriad
11.8. Transgene SA
11.9. Lokon Pharma AB
11.10. Pfizer Inc
11.11. Roche